COVID-19: “Things are different this time”


COVID-19 : “Things are different this time”


Nov. 25, 2020

Global Korean Post


Over the past week, labs across Canada have tested an average of over 75,500 people daily, with 7.6% testing positive.

There have been 342,444 cases of COVID-19 in Canada, including 11,618 deaths. Nationally, there are close to 57,435 active cases across the country as of Nov. 24, 2020.

The new cases of COVID-19 in Canada on Nov. 24, were  4,889 cases and new deaths, 97.  There were over 1,300 new cases reported for Saturday and Sunday.


The Chief Public Health Officer said, “Following last week’s epidemiology and modelling update, it’s clear that we need to strengthen our response. Specifically, to bring down the rapid rate of growth, we need to combine a range of public health measures with tightened prevention practices by individual Canadians.”

But things are different this time; there are more regions of the country with high infection rates and it is clear that COVID-19 knows no bounds. Communities, jurisdictions and whole regions that were little, if at all, impacted in the past are now seeing community spread.

“There has also been a change in the age trend. In the early days of this resurgence, we saw high rates of infection among young adults. Now we are seeing an increase in rates in older adults aged 80 years and older, who are at much higher risk of serious complications and death.”

“Most importantly, we know that public participation is vital to success.”


Prime Minister Justin Trudeau said that vaccination in Canada slated for 2021 would be much later than other countries.

Because that unlike countries like the U.S., Great Britain and Germany, Canada no longer has domestic vaccine mass production capacity.

He added that those countries will prioritize the vaccination of their own citizens over exporting doses around the world.

The prime minister underscores that his government has invested in Canada’s pharmaceutical industry in order to restore domestic mass production of vaccines in the event of another pandemic